scholarly article | Q13442814 |
P356 | DOI | 10.1210/ME.2005-0231 |
P8608 | Fatcat ID | release_jmwlcfjogjbubfv64yew3wh4i4 |
P698 | PubMed publication ID | 16081517 |
P5875 | ResearchGate publication ID | 7677605 |
P2093 | author name string | Iain J McEwan | |
Jennifer Duff | |||
P433 | issue | 12 | |
P921 | main subject | ligand binding | Q61659151 |
P304 | page(s) | 2943-2954 | |
P577 | publication date | 2005-08-04 | |
P1433 | published in | Molecular Endocrinology | Q3319475 |
P1476 | title | Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions | |
P478 | volume | 19 |
Q90626761 | A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy |
Q37210787 | A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin |
Q38534949 | Androgen receptor aberrations in the era of abiraterone and enzalutamide |
Q38116575 | Androgen receptor modulators: a marriage of chemistry and biology |
Q38977288 | Androgen receptor variation affects prostate cancer progression and drug resistance |
Q36905832 | BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients |
Q58708797 | Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models |
Q92091276 | Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models |
Q38844202 | Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy |
Q28534575 | Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor |
Q39355407 | Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer |
Q53282043 | Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes. |
Q42069568 | Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade. |
Q36508759 | Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients |
Q33984776 | Intrinsic disorder in the androgen receptor: identification, characterisation and drugability |
Q46882539 | Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. |
Q27646416 | Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone |
Q57112111 | Molecular Subtypes of Prostate Cancer |
Q40386419 | Neofunctionalization of Androgen Receptor by Gain-of-Function Mutations in Teleost Fish Lineage. |
Q37272639 | Pleiotropic functional properties of androgen receptor mutants in prostate cancer. |
Q55439000 | Precision medicine applications in prostate cancer. |
Q88817029 | Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making |
Q26773613 | Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics |
Q37142544 | RNA editing of androgen receptor gene transcripts in prostate cancer cells |
Q34495028 | Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. |
Q39642231 | Regulation of the androgen receptor by SET9-mediated methylation |
Q53393993 | Resistance to Hormonal Therapy in Prostate Cancer. |
Q38309205 | Switching and withdrawing hormonal agents for castration-resistant prostate cancer. |
Q37577716 | The Drosophila Accessory Gland as a Model for Prostate Cancer and Other Pathologies |
Q34189517 | The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity |
Q37590123 | The role of androgen receptor mutations in prostate cancer progression. |
Q37726336 | The roles and action mechanisms of p160/SRC coactivators and the ANCCA coregulator in cancer |
Q38140106 | The transcriptional programme of the androgen receptor (AR) in prostate cancer |
Q26795611 | Therapy escape mechanisms in the malignant prostate |
Q33745234 | Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer |
Q38259197 | Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level |
Q38925848 | Wild-type and specific mutant androgen receptor mediates transcription via 17β-estradiol in sex hormone-sensitive cancer cells. |
Search more.